Previous 10 | Next 10 |
Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-cla...
2023-11-17 16:16:33 ET Summary Protalix shows mixed financials with declining revenue, yet improved operating loss, indicating increasing operational efficiency. PRX-115, in Phase I trials for refractory gout, is crucial in a competitive market with high efficacy and safety standa...
2023-11-06 11:57:05 ET Protalix Biotherapeutics, Inc. (PLX) Q3 2023 Earnings Conference Call November 6, 2023 8:30 AM ET Company Participants Chuck Padala - Managing Director, Investor Relations Dror Bashan - President and Chief Executive Officer Eyal Rubin - Sen...
2023-11-06 10:01:49 ET More on Health Care Select Sector SPDR Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Stocks to watch in the Health Care sector as earnings close in F...
2023-11-06 08:17:52 ET Losers: MoonLake Immunotherapeutics ( MLTX ) -30% . Tecnoglass ( TGLS ) -15% after Q3 earning release . Kodiak Sciences ( KOD ) -11% says Phase 3 trial for lead asset met key goals. Arrival ( ARVL ) -9% . A...
2023-11-06 06:53:00 ET More on Protalix BioTherapeutics Protalix BioTherapeutics Stock Is A Hold Pending Successful Commercialization Of Elfabrio Nano-X, InMode, Teva among notable Israel-based healthcare decliners Seeking Alpha’s Quant Rating on Protalix BioT...
2023-10-31 15:49:03 ET A New Jersey-based %Healthcare company turned heads on Tuesday following HC Wainwright & Co. maintaining a buy rating while raising its price target from $7 to $10/share. This report came one day following the company’s announcement that it will be rele...
2023-10-31 12:24:58 ET Summary Amicus Therapeutics, Inc. is a commercial-stage biotech company focused on developing therapies for rare diseases. The company recently received FDA approval for its combination therapy Pombiliti + Opfolda for Pompe disease. Amicus Therapeutics i...
Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023 PR Newswire Company to host conference call and webcast at 8:30 a.m. EST CARMIEL, Israel , Oct. 30, 2023 /PRNewswire/ -- Protalix BioTherapeutic...
2023-10-20 10:06:59 ET More on Health Care: Health Care Select Sector Fund ETF: Riding The Healthcare Boom September Labor Report Preview: Full Employment To Infinity Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Stocks to watch in the...
News, Short Squeeze, Breakout and More Instantly...
Protalix BioTherapeutics Inc. Company Name:
PLX Stock Symbol:
NYSE Market:
Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results PR Newswire Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel , March 14, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE Ameri...
Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024 PR Newswire Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel , March 7, 2024 /PRNewswire/ -- Protalix BioTherapeutics, I...
Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference PR Newswire Corporate presentation scheduled for Monday, February 26, 2024 at 1:00 PM ET ...